Table 1.
Baseline characteristics of patients in each of the cohorts
| Characteristic | HER2-targeted therapy (n = 430) (%) | No HER2-targeted therapy (n = 1497) (%) | p-value |
|---|---|---|---|
| Age (years) | 0.601 | ||
| ≤ 50 | 92 (21.4%) | 303 (20.2%) | |
| > 50 | 338 (78.6%) | 1194 (79.8%) | |
| Race | 0.778 | ||
| Caucasian | 371 (86.3%) | 1271 (84.9%) | |
| African American | 41 (9.5%) | 157 (10.5%) | |
| Other/ not recorded | 18 (4.2%) | 69 (4.6%) | |
| Charlson-Deyo Score | 0.813 | ||
| 0 | 374 (87.0%) | 1319 (88.1%) | |
| 1 | 50 (11.6%) | 18 (10.6%) | |
| ≥ 2 | 6 (1.4%) | 20 (1.3%) | |
| Insurance | 0.670 | ||
| Medicaid | 25 (5.8%) | 86 (5.7%) | |
| Private | 274 (63.7%) | 902 (60.3%) | |
| Medicare | 116 (27.0%) | 455 (30.4%) | |
| Uninsured | 8 (1.9%) | 24 (1.6%) | |
| Government/other | 7 (1.6%) | 30 (2.0% | |
| Income | 0.457 | ||
| ≤ 62999 USD | 281 (65.4%) | 938 (62.7%) | |
| ≥ 63000 USD | 147 (34.2%) | 555 (37.1%) | |
| Not recorded | 2 (0.5%) | 4 (0.3%) | |
| Facility type | 0.432 | ||
| Academic | 108 (25.1%) | 417 (27.9%) | |
| Non-academic | 317 (73.7%) | 1068 (71.3%) | |
| Not recorded | 5 (1.2%) | 12 (0.8%) | |
| Margin status | 0.306 | ||
| Negative | 416 (96.7%) | 1440 (96.2%) | |
| Positive | 10 (2.3%) | 50 (3.3%) | |
| Not recorded | 4 (0.9%) | 7 (0.5%) | |
| Hormonal therapy | 0.898 | ||
| Yes | 220 (51.2%) | 777 (51.9%) | |
| No | 167 (38.8%) | 581 (38.8%) | |
| Not recorded | 43 (10.0%) | 139 (9.3%) | |
| Estrogen receptor status | 0.034 | ||
| Positive | 261 (60.7%) | 992 (66.3%) | |
| Negative | 169 (39.3%) | 499 (33.3%) | |
| Not recorded | 0 (0.0%) | 6 (0.4%) | |
| Progesterone receptor status | 0.665 | ||
| Positive | 199 (46.3%) | 726 (48.5%) | |
| Negative | 221 (51.4%) | 742 (49.6%) | |
| Not recorded | 10 (2.3%) | 29 (1.9%) | |
| Grade | 0.295 | ||
| 1 | 13 (3.0%) | 57 (3.8%) | |
| 2 | 65 (15.1%) | 278 (18.6%) | |
| 3 | 275 (64.0%) | 897 (59.9%) | |
| Not recorded | 77 (17.9%) | 265 (17.7%) | |